Researchers at Northwestern Medicine have discovered immune system markers that may help predict whether patients with bladder cancer will respond to Bacillus Calmette-Guérin (BCG) therapy, according to findings published in the Journal of Clinical Investigation. The discovery could lead to more personalized treatment strategies for the nearly 80,000 Americans diagnosed with bladder cancer each year.
BCG therapy, a form of immunotherapy, has been the standard treatment for non-muscle invasive bladder cancer for decades. However, it fails in up to 40% of patients, leading to disease progression and the need for more aggressive interventions like cystectomy. The ability to identify non-responders early could spare them from ineffective treatment and its side effects, while allowing them to pursue alternative therapies sooner.
The study, led by researchers at Northwestern University Feinberg School of Medicine, analyzed tumor samples from bladder cancer patients undergoing BCG therapy. They identified specific immune cell populations and gene expression patterns that correlated with treatment response. Notably, patients who responded to BCG had higher levels of certain T cells and natural killer cells within their tumors, as well as distinct cytokine profiles.
“These biomarkers could help us determine who is likely to benefit from BCG and who might need a different approach,” said the study’s lead author. “This moves us closer to precision medicine for bladder cancer.”
The implications extend beyond patient care. For the pharmaceutical industry, predictive biomarkers could accelerate clinical trials by enriching for patients likely to respond to immunotherapy, reducing trial sizes and costs. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are actively developing next-generation immunotherapies that might benefit from such biomarkers, potentially leading to more effective combination treatments.
The findings also highlight the growing role of immune profiling in oncology. As immunotherapy becomes more prevalent, understanding the tumor immune microenvironment is critical. This research provides a foundation for developing blood-based tests that could non-invasively monitor immune status during treatment.
While the results are promising, the researchers caution that larger studies are needed to validate the biomarkers before they can be used in clinical practice. However, the study represents a significant step toward improving outcomes for bladder cancer patients, who currently face limited options when BCG fails.
The team plans to expand their work to other immunotherapies and cancer types, aiming to create a universal immune signature for treatment response. For now, the findings offer hope that more personalized, effective bladder cancer therapy is on the horizon.
